Physician
Polyclinic Medical Center, INC.
Polyclinic Medical Center, INC. was paid $4.75M by Medicaid between Jan 2018 and Oct 2024, across 108 billing codes. Its largest line is 99214, doctor's office visit, returning patient (more involved) — 40% of everything it billed.
33Billing provider infoPOLYCLINIC MEDICAL CENTER, INC.
BAKERSFIELD, CA 93305
BAKERSFIELD, CA 93305
33aNPI1750308656assigned 07/16/2006
33bProvider typeFamily Medicine Physician
28Total paid$4.75M
24GClaims233,027
24DCodes billed108
24AFirst – last monthJan 2018 – Oct 2024
Compared with peers
Next to other Family Medicine Physician providers in California
Rank by total paid#74 of 2,511
Median peer was paid$13K
This provider vs. median370×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 44,966 | $579K | |
| 2019 | 45,382 | $620K | |
| 2020 | 27,197 | $506K | |
| 2021 | 18,247 | $507K | |
| 2022 | 19,398 | $653K | |
| 2023 | 37,755 | $672K | |
| 2024incomplete | 40,082 | $1.22M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99214 | Doctor's office visit, returning patient (more involved)Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity | 40% | 41,545 | 36,289 | $1.91M |
| 99213 | Doctor's office visit, returning patient (routine)Office or other outpatient visit for the evaluation and management of an established patient, low complexity | 19% | 22,478 | 19,670 | $890K |
| G0447 | Face-to-face behavioral counseling for obesity, 15 minutes | 6.4% | 13,622 | 12,048 | $305K |
| 87633 | Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets | 5.1% | 847 | 830 | $243K |
| 99396 | Periodic comprehensive preventive medicine reevaluation, established patient, 40-64 years | 5.0% | 2,131 | 2,065 | $236K |
| 99395 | Periodic comprehensive preventive medicine reevaluation, established patient, 18-39 years | 3.3% | 1,403 | 1,359 | $159K |
| G0442 | Annual alcohol misuse screening, 5 to 15 minutes | 2.4% | 6,116 | 5,984 | $115K |
| 93000 | 2.1% | 2,992 | 2,921 | $98K | |
| 99394 | Periodic comprehensive preventive medicine reevaluation, established patient, adolescent (12-17 years) | 1.9% | 1,219 | 1,155 | $89K |
| 90750 | 1.8% | 431 | 430 | $87K | |
| 90688 | 1.4% | 3,221 | 3,183 | $67K | |
| 99393 | Periodic comprehensive preventive medicine reevaluation, established patient, late childhood (5-11 years) | 1.3% | 1,076 | 1,002 | $61K |
96 more codes
| 92552 | 1.1% | 2,554 | $54K | |
| 82947 | 1.0% | 17,040 | $48K | |
| 90732 | <1% | 258 | $39K | |
| G8431 | Screening for depression is documented as being positive and a follow-up plan is documented | <1% | 990 | $29K |
| G0444 | Annual depression screening, 5 to 15 minutes | <1% | 1,600 | $27K |
| 90686 | <1% | 1,043 | $25K | |
| 90662 | <1% | 372 | $24K | |
| J3301 | Injection, triamcinolone acetonide, not otherwise specified, 10 mg | <1% | 2,381 | $23K |
| J7307 | Etonogestrel (contraceptive) implant system, including implant and supplies | <1% | 15 | $18K |
| 90715 | <1% | 492 | $17K | |
| 94060 | <1% | 310 | $15K | |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 3,174 | $14K |
| 99173 | <1% | 3,161 | $13K | |
| 99407 | <1% | 549 | $12K | |
| 99406 | <1% | 895 | $12K | |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 1,983 | $12K |
| 99392 | Periodic comprehensive preventive medicine reevaluation, established patient, early childhood (1-4 years) | <1% | 205 | $9K |
| 92551 | <1% | 648 | $9K | |
| 80305 | <1% | 760 | $7K | |
| 81002 | <1% | 4,180 | $7K | |
| G8510 | Screening for depression is documented as negative, a follow-up plan is not required | <1% | 1,329 | $7K |
| 0012A | <1% | 151 | $6K | |
| 0011A | <1% | 172 | $6K | |
| 90658 | <1% | 216 | $5K | |
| 99203 | Doctor's office visit, new patient (routine) | <1% | 125 | $5K |
| 90673 | <1% | 83 | $4K | |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 295 | $4K |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 578 | $4K |
| 90651 | <1% | 328 | $4K | |
| 11981 | <1% | 15 | $4K | |
| 0013A | <1% | 89 | $3K | |
| 85018 | <1% | 2,001 | $3K | |
| 99385 | <1% | 26 | $3K | |
| 90670 | <1% | 44 | $3K | |
| G2023 | Specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | <1% | 105 | $2K |
| 99386 | <1% | 13 | $2K | |
| 90734 | <1% | 188 | $2K | |
| 96110 | Developmental screening, with scoring and documentation, per standardized instrument | <1% | 24 | $2K |
| 0001A | <1% | 39 | $2K | |
| 87631 | <1% | 29 | $1K | |
| 90682 | <1% | 14 | $1K | |
| 81025 | <1% | 442 | $1K | |
| J0690 | Injection, cefazolin sodium, 500 mg | <1% | 206 | $1K |
| 90620 | <1% | 51 | $1K | |
| Z1034 | <1% | 19 | $1K | |
| 0002A | <1% | 21 | $840.00 | |
| 99391 | Periodic comprehensive preventive medicine reevaluation, established patient, infant (under 1 year) | <1% | 13 | $531.17 |
| 90648 | <1% | 45 | $477.45 | |
| 90630 | <1% | 16 | $476.16 | |
| 99442 | <1% | 40 | $470.67 | |
| 99401 | <1% | 926 | $299.06 | |
| 90700 | <1% | 28 | $293.40 | |
| 87070 | <1% | 26 | $195.26 | |
| 3078F | <1% | 5,579 | $157.41 | |
| 90716 | <1% | 13 | $140.40 | |
| 90707 | <1% | 12 | $129.60 | |
| 3008F | <1% | 29,460 | $127.36 | |
| 3074F | <1% | 5,620 | $99.98 | |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 19 | $91.78 |
| 3077F | <1% | 10,214 | $88.35 | |
| 3080F | <1% | 9,349 | $71.18 | |
| 4050F | <1% | 3,766 | $52.41 | |
| 3075F | <1% | 1,214 | $41.56 | |
| 3079F | <1% | 1,932 | $24.35 | |
| 3044F | <1% | 1,318 | $9.26 | |
| 1123F | <1% | 8,739 | $9.26 | |
| J7613 | Albuterol, inhalation solution, fda-approved final product, non-compounded, administered through dme, unit dose, 1 mg | <1% | 126 | $5.62 |
| 4010F | 0% | 54 | $0.00 | |
| 1000F | 0% | 1,156 | $0.00 | |
| 1157F | 0% | 43 | $0.00 | |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | 0% | 2,071 | $0.00 |
| G0008 | Administration of influenza virus vaccine | 0% | 75 | $0.00 |
| 1036F | 0% | 1,531 | $0.00 | |
| 3014F | 0% | 77 | $0.00 | |
| 3052F | 0% | 13 | $0.00 | |
| 1111F | 0% | 267 | $0.00 | |
| 1034F | 0% | 39 | $0.00 | |
| G9691 | Patient had hospice services any time during the measurement period | 0% | 40 | $0.00 |
| 3061F | 0% | 21 | $0.00 | |
| G8754 | Most recent diastolic blood pressure < 90 mmhg | 0% | 243 | $0.00 |
| G8428 | Current list of medications not documented as obtained, updated, or reviewed by the eligible clinician, reason not given | 0% | 86 | $0.00 |
| G0439 | Annual wellness visit, includes a personalized prevention plan of service (pps), subsequent visit | 0% | 20 | $0.00 |
| Q0091 | Screening papanicolaou smear; obtaining, preparing and conveyance of cervical or vaginal smear to laboratory | 0% | 209 | $0.00 |
| G8752 | Most recent systolic blood pressure < 140 mmhg | 0% | 180 | $0.00 |
| G8427 | Eligible clinician attests to documenting in the medical record they obtained, updated, or reviewed the patient's current medications | 0% | 483 | $0.00 |
| G9991 | Patient received any pneumococcal conjugate or polysaccharide vaccine on or after their 19th birthday and before the end of the measurement period | 0% | 569 | $0.00 |
| 3051F | 0% | 40 | $0.00 | |
| 90472 | Immunization administration, each additional vaccine (list separately) | 0% | 526 | $0.00 |
| 3046F | 0% | 58 | $0.00 | |
| G0101 | Cervical or vaginal cancer screening; pelvic and clinical breast examination | 0% | 167 | $0.00 |
| G8753 | Most recent systolic blood pressure >= 140 mmhg | 0% | 42 | $0.00 |
| G0402 | Initial preventive physical examination; face-to-face visit, services limited to new beneficiary during the first 12 months of medicare enrollment | 0% | 136 | $0.00 |
| 4040F | 0% | 13 | $0.00 | |
| 99072 | 0% | 74 | $0.00 | |
| G8482 | Influenza immunization administered or previously received | 0% | 32 | $0.00 |
| G8417 | Bmi is documented above normal parameters and a follow-up plan is documented | 0% | 13 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialNAHER, KAMRUN (DIRECTOR)